
WHAT IS CLAIMED IS:

1. A compound according to Formula (I)



(I),

or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof, wherein:

m, and n are independently an integer selected from the group consisting of 0, 1, 2, and 3;

p, and q are independently an integer selected from the group consisting of 0, 1, 2, 3, and 4;

$R_2$, $R_{2a}$, $R_{2b}$, $R_{2c}$ and $R_{2d}$ are independently selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, nitro, unsubstituted or substituted $C_{1-6}$ alkyl, unsubstituted or substituted $C_{1-6}$ haloalkyl, unsubstituted or substituted $C_{1-6}$ hydroxyalkyl, unsubstituted or substituted $C_{2-6}$ alkenyl, unsubstituted or substituted $C_{2-6}$ alkenyloxy, unsubstituted or substituted $C_{2-6}$ alkynyl, unsubstituted or substituted $C_{2-6}$ alkynyloxy, unsubstituted or substituted $C_{1-8}$ alkoxy, unsubstituted or substituted $C_{3-6}$ cycloalkyl, unsubstituted or substituted $C_{3-6}$ heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, wherein $R_2$ is not hydrogen, hydroxy or benzyloxy; or $R_2$ and $R_{2b}$ or $R_{2c}$, taken together with the atoms to which they are attached form a ring system; or $R_{2a}$ and $R_{2b}$, or $R_{2c}$ and $R_{2d}$, taken together with the atoms to which they are attached form a ring system;

$R_3$ is selected from hydrogen, deuterium, hydroxyl, -OD, unsubstituted or substituted $C_{1-6}$ alkyl, unsubstituted or substituted $C_{1-6}$ haloalkyl, unsubstituted or substituted $C_{1-6}$ hydroxyalkyl, unsubstituted or substituted $C_{2-6}$ alkenyl, unsubstituted or substituted $C_{3-6}$ cycloalkyl, unsubstituted or substituted $C_{3-6}$ heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;


$R_{4a}$, $R_{4b}$, $R_{5a}$, and $R_{5b}$, are independently selected from the group consisting of hydrogen, deuterium, and unsubstituted or substituted $C_{1-6}$ alkyl; wherein when m and n are 1 then $R_{4a}$, $R_{4b}$, $R_{5a}$, $R_{5b}$ are hydrogen;

$R_6$ is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, oxo, -OD, cyano, substituted or unsubstituted $C_{1-4}$ alkyl, and substituted or unsubstituted $C_{1-4}$ alkoxy, substituted or unsubstituted aryl; or $R_6$ and $R_3$, taken together with the atoms to which they are attached form a ring system;
$R_7$ is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, oxo, -OD, cyano, substituted or unsubstituted $C_{1-4}$ alkyl, and substituted or unsubstituted $C_{1-4}$ alkoxy;
$R_8$ is absent, or selected from the group consisting of hydrogen, deuterium, cyano, hydroxyl, -OD, substituted or unsubstituted $C_{1-4}$ alkyl, substituted or unsubstituted $C_{2-4}$ alkenyl, substituted or unsubstituted $C_{3-6}$ cycloalkyl, and substituted or unsubstituted $C_{1-4}$ alkoxy;
X is O or S; and
wherein $R_1$ and $R_{1d}$ are fluoro, and $R_{1a}$, $R_{1b}$ and $R_{1c}$ are hydrogen.


2. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to claim 1, wherein $R_2$ is selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, unsubstituted or substituted $C_{1-6}$ alkyl, unsubstituted or substituted $C_{1-6}$ haloalkyl, unsubstituted or substituted $C_{1-6}$ hydroxyalkyl, unsubstituted or substituted $C_{2-6}$ alkenyl, unsubstituted or substituted $C_{1-6}$ alkoxy, unsubstituted or substituted $C_{3-6}$ cycloalkyl, unsubstituted or substituted $C_{3-6}$ heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
$R_{2d}$ is selected from the group consisting of hydrogen, deuterium, amino, hydroxyl, -OD, halogen, cyano, unsubstituted or substituted $C_{1-6}$ alkyl, unsubstituted or substituted $C_{1-6}$ haloalkyl, unsubstituted or substituted $C_{1-6}$ hydroxyalkyl, unsubstituted or substituted $C_{2-6}$ alkenyl, unsubstituted or substituted $C_{1-6}$ alkoxy, unsubstituted or substituted $C_{3-6}$ cycloalkyl, unsubstituted or substituted $C_{3-6}$ heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
$R_{2a}$, $R_{2b}$, and $R_{2c}$ are hydrogen, and $R_{2d}$ is not hydrogen; or $R_{2a}$, $R_{2c}$ and $R_{2d}$ are hydrogen and $R_2$ and $R_{2b}$, taken together with the atoms to which they are attached form a heteroalicyclic or heteroaryl ring system.

3. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to claim 1 or 2, wherein $R_2$, $R_{2a}$, $R_{2b}$,


$R_{2c}$ and $R_{2d}$ independently are selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenyloxy, $C_{1-6}$ alkynyloxy $C_{1-6}$ haloalkoxy, $C_{3-4}$ cycloalkyl, $C_{3-4}$ cycloalkyl-$C_{1-3}$ alkyl and deuterated analogues thereof; or $R_2$ and $R_{2b}$, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system that has the following formulae:





(III) ,





(IV),




(V),




(VI) or




(VII),

wherein $R_{12a}$, $R_{12b}$, $R_{12c}$, $R_{13a}$, $R_{13b}$, $R_{14a}$, and $R_{14b}$ independently are absent or selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, $C_{1-4}$ alkyl, and $C_{1-4}$ alkoxy, and wherein $Z_1$, $Z_2$ and $Z_3$ independently are selected from the group consisting of C, N, O and S.

4. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-3, wherein the formed ring system is of Formula (III), and both $R_{12a}$ and $R_{12b}$ are hydrogen or methyl, and both $R_{13a}$ and $R_{13b}$ are hydrogen or methyl.

5. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-4, wherein $R_{2a}$, $R_{2c}$, $R_{2d}$, and $R_{2b}$, provided $R_{2b}$ is not forming a ring system with $R_2$, independently are selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, methyl, -$CD_3$, methoxy, -$OCD_3$,-$OCF_3$ and -$CF_3$.


6. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-5, wherein $R_{2a}$, $R_{2c}$ and $R_{2b}$ are hydrogen, and $R_{2d}$ is hydrogen, fluoro or hydroxyl.

7. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-3, wherein one of $R_{2a}$ and $R_{2b}$ is fluoro and the other is hydrogen, and $R_{2c}$ and $R_{2d}$ are hydrogen.

8. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-7, wherein $R_2$, provided $R_2$ is not forming a ring system with $R_{2b}$, is selected from the group consisting of halogen, cyano, methyl, -$CD_3$, ethyl, -$CD_2CD_3$, optionally deuterated n-propyl, optionally deuterated iso-propyl, optionally deuterated n-butyl, optionally deuterated iso-butyl, optionally deuterated n-pentyl, optionally deuterated 2-methyl-butyl, optionally deuterated n-hexyl, optionally deuterated 2-methyl-pentyl, optionally deuterated methoxy, optionally deuterated ethoxy, optionally deuterated n-propoxy, optionally deuterated isopropoxy, optionally deuterated allyloxy, optionally deuterated prop-2-yn-1-yloxy, optionally deuterated n-butoxy, optionally deuterated iso-butoxy, optionally deuterated tert-butoxy, optionally deuterated pentyl-oxy, optionally deuterated 4-methyl-butoxy, optionally deuterated hexyl-oxy, optionally deuterated 4-methylpentoxy, optionally deuterated cyclopropyloxy, optionally deuterated cyclopropylmethoxy, optionally deuterated cyclopropylethoxy, optionally deuterated cyclobutyloxy, optionally deuterated cyclobutyloxy, optionally deuterated cyclobutylmethoxy, optionally deuterated cyclobutylethoxy, optionally deuterated $C_{1-6}$ haloalkoxy, -$OCF_3$, -$OCF_2CF_3$, -$OCHF_2$, -$OCDF_2$, -$CF_3$, -$CF_2CF_3$, -$CHF_2$, $CDF_2$ -$CH_2CF_3$, -$CD_2CF_3$, –$CH_2F$, -$CF_2CH_3$ 1,1,2,2-tetrafluorobutyl and 1,1,1,2,2-pentafluorobutyl.

9. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-8, wherein $R_2$, provided $R_2$ is not forming a ring system with $R_{2b}$, is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, prop-2-yn-1-yloxy, n-butoxy, iso-butoxy, tert-butoxy, pentyl-oxy, 4-methyl-butoxy, hexyl-oxy, 4-methylpentoxy, cyclopropyloxy, cyclopropylmethoxy, cyclopropylethoxy, cyclobutyloxy, cyclobutylmethoxy, cyclobutylethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy, 4-methoxybutoxy, 2-hydroxyethoxy, 1,2-dihydroxyethyl, 2-hydroxy-2,3-dimethylbutoxy, $-OCF_3$ and (1,3-difluoropropan-2-yl)oxy.




10. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-9, wherein $R_2$ is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, prop-2-yn-1-yloxy, n-butoxy, iso-butoxy, tert-butoxy, pentyl-oxy, 4-methyl-butoxy, hexyl-oxy, 4-methylpentoxy, cyclopropyloxy, cyclopropylmethoxy, cyclopropylethoxy, cyclobutyloxy, cyclobutylmethoxy, cyclobutylethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy, 4-methoxybutoxy, 2-hydroxyethoxy, 1,2-dihydroxyethyl, 2-hydroxy-2,3-dimethylbutoxy, $-OCF_3$ and (1,3-difluoropropan-2-yl)oxy; and $R_{2a}$, $R_{2b}$, $R_{2c}$ and $R_{2d}$ are hydrogen; or $R_2$ and $R_{2b}$, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system, that has the following general formula:



(III),

wherein $R_{12a}$ and $R_{12b}$ are hydrogen or methyl, and both $R_{13a}$ and $R_{13b}$ are hydrogen or methyl, and $R_{2a}$, $R_{2c}$ and $R_{2d}$ are hydrogen.

11. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-10, wherein $R_2$ is selected from the group consisting of ethoxy, isopropoxy, n-propoxy, allyloxy, n-butoxy, iso-

butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy and 2,2-difluoroethoxy, $R_{2a}$, $R_{2b}$, $R_{2c}$ and $R_{2d}$ are hydrogen; or $R_2$ and $R_{2b}$, taken together with the phenyl ring they attach to and the atoms to which they are attached form a bicyclic fused ring system, that, has the following formulae  (IIIa),  (IIIb), and  (IIIc), and $R_{2a}$, $R_{2c}$ and $R_{2d}$ are hydrogen.

12. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-10, wherein $R_2$ is selected from the group consisting of ethoxy, n-propoxy, isopropoxy, allyloxy, iso-butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 2,2-difluoroethoxy; or $R_2$ and $R_{2b}$, taken together with the phenyl ring they attach to and the atoms to which they are attached form unsubstituted 2,3-dihydrobenzofuran-5-yl, unsubstituted benzofuran-5-yl, and unsubstituted 2,2-dimethyl-2,3-dihydrobenzofuran-5-yl.

13. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein halogen is fluoro.

14. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-13, wherein $R_3$ is selected from the group consisting of hydrogen, deuterium, hydroxyl, -OD, substituted or unsubstituted $C_{1-6}$ alkyl, substituted or unsubstituted $C_{1-6}$ alkoxy, substituted or unsubstituted -$(CH_2)_s$-$C_{3-6}$ cycloalkyl, substituted or unsubstituted -$(CH_2)_s$-$C_{2-5}$ heteroalicyclyl, substituted or unsubstituted -$(CH_2)_s$-$C_{2-5}$ heteroaryl, and substituted or unsubstituted -$(CH_2)_s$-$C_{5-6}$ aryl, wherein each s is selected from the group consisting of 0, 1, 2 and 3.

15. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-14, wherein $R_3$ is selected from the group consisting of hydrogen, methyl, -$CD_3$. ethyl, -$CD_2CD_3$, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein $R_{9a}$ ,$R_{9b,}$ and $R_{9c}$ independently are hydrogen or $C_{1-4}$-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

16. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-15, wherein $R_3$ is hydrogen or methyl.

17. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-16, wherein $R_{4a}$, $R_{4b}$, $R_{5a}$ and $R_{5b}$ are independently hydrogen or methyl.

18. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-17, wherein $R_{4a}$, $R_{4b}$ and $R_{5a}$ are hydrogen and $R_{5b}$ is methyl or hydrogen.

19. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-17, wherein $R_{4a}$, $R_{5a}$ and $R_{5b}$ are hydrogen and $R_{4b}$ is methyl or hydrogen.

20. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-19, wherein $R_{4a}$, $R_{4b}$, $R_{5a}$ and $R_{5b}$ are hydrogen.

21. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-20, wherein q is 0, or $R_6$ is selected from halogen and $C_{1-4}$ alkyl.

22. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-21, wherein q is 1.

23. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to claim 22, wherein $R_6$ is fluoro.

24. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-23, wherein p is 0.

25. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-24, wherein $R_8$ is selected from the group consisting of hydrogen, halogen, methyl, ethyl, propyl, methoxy, ethoxy, $C_{1\text{-}2\text{-}}$ haloalkyl, and $C_{1\text{-}2\text{-}}$ haloalkoxy.

26. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-25, wherein $R_8$ is selected from the group consisting of hydrogen, $-CF_3$, $-CHF_2$, $-CF_2CF_3$ $-OCF_3$, $-OCF_2CF_3$ and $-OCHF_2$.

27. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-26, wherein $R_8$ is hydrogen.

28. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-27, wherein X is O.

29. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-28, wherein m, and n independently are selected from the group consisting of 0 and 1.

30. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-29, wherein m is 1 and n is 0 or 1.

31. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein:
$R_{4a}$, $R_{4b}$, $R_{5a}$, $R_{5b}$, $R_6$, $R_7$, $R_8$ are each hydrogen;
m and n are each 1;
p and q are 0 or 1;
X is O; and
$R_3$ is selected from the group consisting of hydrogen, methyl, -$CD_3$. ethyl, -$CD_2CD_3$, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein $R_{9a}$ ,$R_{9b,}$ and $R_{9c}$ independently are hydrogen or $C_{1-4}$-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

32. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-12, wherein:
$R_{4a}$, $R_{4b}$, $R_{5a}$, $R_{5b}$, $R_6$, $R_7$, $R_8$ are each hydrogen;
m and n are each 1;
p and q are 0;
X is O; and
$R_3$ is selected from the group consisting of hydrogen, methyl, -$CD_3$. ethyl, -$CD_2CD_3$, n-propyl, -$CD_2CD_2CD_3$, iso-propyl, cyclopropyl, -$CDCD_3CD_3$, –$(CR_{9a}R_{9b})_tC(=O)OR_{9c}$ and –$(CH_2)_tC(=O)NR_{9a}R_{9b}$, wherein $R_{9a}$ ,$R_{9b,}$ and $R_{9c}$ independently are hydrogen or $C_{1-4}$-alkyl, wherein each t is selected from the group consisting of 0, 1, 2 and 3.

33. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to claim 31 or 32, wherein $R_3$ is methyl or hydrogen.

34. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 31- 33, wherein $R_2$ is selected from the group consisting of ethoxy, n-propoxy, isopropoxy, allyloxy, iso-butoxy, tert-butoxy, cyclopropyloxy, cyclopropylmethoxy, 2-fluoroethoxy, 3-fluoropropoxy and 2,2-difluoroethoxy; or $R_2$ and $R_{2b}$, taken together with the phenyl ring they attach to and the atoms to which they are attached form unsubstituted 2,3-dihydrobenzofuran-5-yl, unsubstituted benzofuran-5-yl, and unsubstituted 2,2-dimethyl-2,3-dihydrobenzofuran-5-yl.

35. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-34, having a hERG % inhibition of less than 65 %, such as less than 50 %, such as less than 40 %, such as less than 30%.

36. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-34, having a hERG % inhibition of less than 65 %, such as less than 50 %, such as less than 40 %, such as less than 30%, and a 5-HT2A pKi of 8.4 or greater

37. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to claim 1, selected from the group consisting of:

1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)-phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-methylpropoxy)phenyl]methyl}-1-(piperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]-methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-fluoroethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-ethoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-(4-(allyloxy)benzyl)-1-(2,4-difluorobenzyl)-1-(1-methylpiperidin-4-yl)urea;
3-[(1-benzofuran-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-methyl-1,3-benzoxazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-2,3-dihydro-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1,2-benzoxazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,2-dimethyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[1-(2,4-difluorophenyl)ethyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-[(quinolin-6-yl)methyl]urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-1,2-benzoxazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzoxazol-6-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzoxazol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-7-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(2,2-dimethyl-2H-chromen-7-yl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-methyl-1H-indol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,1-dioxo-2,3-dihydro-1$\lambda^6$-benzothiophen-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1H-inden-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(1,3-benzothiazol-6-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2H-indazol-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-methyl-2H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-{[2-($^2H_3$)methyl(1,1,1,3,3,3-$^2H_6$)propan-2-yl]oxy}phenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-cyclopropoxyphenyl)methyl]-1-[(1R)-1-(2,4-difluorophenyl)ethyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(3-cyano-4-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;

3-[(2-chloro-4-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

3-[(2,4-difluorophenyl)methyl]-1-[(2-fluoro-4-nitrophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-1,3-benzodiazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(1-methyl-1H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-[(4-methoxyphenyl)methyl]-1-(piperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-{[4-($^{2}H_{3}$)methoxyphenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-{[2-methoxy-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-1-{1-[(1,1,1,3,3,3-$^{2}H_{6}$)propan-2-yl]piperidin-4-yl}-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;

3-[(1H-1,3-benzodiazol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(7R,8aS)-octahydroindolizin-7-yl]-3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]urea;

1-[(7R,8aS)-octahydroindolizin-7-yl]-1-[(2,4-difluorophenyl)methyl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;

1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(quinoxalin-6-yl)methyl]urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(quinoxalin-6-yl)methyl]urea
3-[(2,4-difluorophenyl)methyl]-3-[(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-1-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-[(3R,4S)-1,3-dimethylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-[(3S,4R)-1,3-dimethylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-(1,4-dimethylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-hydroxy-2,3-dimethylbutoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({3-fluoro-4-[(2-hydroxyethoxy)methyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1H-indazol-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({4-[(1R)-1,2-dihydroxyethyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-({4-[(1S)-1,2-dihydroxyethyl]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(1,3-dihydro-2-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-(3-methoxypropoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-fluoro-4-nitrophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(4-chloro-3-methoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[4-fluoro-2-(trifluoromethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-{[2-methyl-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]urea;
1-[(2,4-difluorophenyl)methyl]-3-[(3-fluoro-4-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2-fluoro-4-hydroxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)-1-[(4-phenoxyphenyl)methyl]urea;
3-[(4-butoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea;
3-[(4-butoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-methoxyphenyl)methyl]-1-(piperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-ethoxyphenyl)methyl]-3-(piperidin-4-yl)urea;
3-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-[1-($^{2}H_{3}$)methylpiperidin-4-yl]-3-{[4-(propan-2-yloxy)phenyl]methyl}urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea;
3-{[4-(cyclopropylmethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[3-fluoro-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[2-fluoro-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-{[3-methyl-4-(propan-2-yloxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(4-fluoro-3-methoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;

1-[(2,4-difluorophenyl)methyl]-3-({4-[(2-ethylhexyl)oxy]phenyl}methyl)-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(prop-2-yn-1-yloxy)phenyl]methyl}urea;
3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea;
1-[(2,6-difluoro-4-methoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-{[4-(3-fluoropropoxy)phenyl]methyl}-3-(1-methylpiperidin-4-yl)urea;
1-{[4-(1,1-difluoroethyl)phenyl]methyl}-3-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-({4-[(1,3-difluoropropan-2-yl)oxy]phenyl}methyl)-3-(1-methylpiperidin-4-yl)urea;
3-{[4-(2,2-difluoroethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-1-(1-methylpiperidin-4-yl)urea;
3-[(2,4-difluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-3-(1-methylpiperidin-4-yl)urea;
1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(piperidin-4-yl)urea;
1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(piperidin-4-yl)urea; and
1-[(2,4-difluorophenyl)methyl]-3-{[2,3-dihydro(2,2,3,3-$^{2}H_{4}$)-1-benzofuran-5-yl]methyl}-1-(1-methylpiperidin-4-yl)urea.

38. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

39. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[(4-propoxyphenyl)methyl]urea, or a

pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

40. The compound according to claim 1, wherein the compound is 3-{[4-(cyclopropylmethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

41. The compound according to claim 1, wherein the compound is 1-[(4-cyclopropoxyphenyl)methyl]-3-[(2,4-difluorophenyl)methyl]-3-(piperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

42. The compound according to claim 1, wherein the compound is 3-{[4-(2,2-difluoroethoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

43. The compound according to claim 1, wherein the compound is 3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

44. The compound according to claim 1, wherein the compound is 3-(4-(allyloxy)benzyl)-1-(2,4-difluorobenzyl)-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

45. The compound according to claim 1, wherein the compound is 3-[(4-cyclopropoxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

46. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-3-{[4-(2-fluoroethoxy)phenyl]methyl}-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

47. The compound according to claim 1, wherein the compound is 3-[(1-benzofuran-5-yl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

48. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-3-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

49. The compound according to claim 1, wherein the compound is 3-[(2,4-difluorophenyl)methyl]-1-{[4-(3-fluoropropoxy)phenyl]methyl}-3-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

50. The compound according to claim 1, wherein the compound is 3-{[4-(tert-butoxy)phenyl]methyl}-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

51. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

52. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-1-(piperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea, or a

pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

53. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-3-[(4-ethoxyphenyl)methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

54. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(propan-2-yloxy)phenyl]methyl}urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

55. The compound according to claim 1, wherein the compound is 1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof.

56. Use of an effective amount of a compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-55, or a composition comprising an effective amount of a compound, pharmaceutically acceptable salt, polymorph or stereoisomer of a compound according to any one of claims 1-55 for the production of a medicament for treating a disease in a patient,
wherein the disease is selected from the group consisting of Abnormal hormonal activity, Alzheimer's disease, Alzheimer’s disease dementia, Alzheimer’s disease psychosis, Addiction (alcohol, cocaine, methamphetamine, nicotine and opioid), Addison’s disease, ADHD, Alzheimer's disease psychosis, Affective disorders, Aggressiveness, Agitation, Akathisia, Alcohol addiction, Alcohol withdrawal, Amenorrhea, Amyotrophic lateral sclerosis, Anhedonia, Anorexia, Anti-NMDAR encephalitis, Anxiety, Appetite disorders, Asthma, Autism, Behavioral disorders, Behavioral disturbances associated with dementia, Binge eating disorder associated with impulse control disorder (ICD), Bipolar disorder, Blindness, Borderline disorder, Borderline

personality disorder, Bradykinesia, Bulimia, Buying associated with ICD, Cardiac arrhythmia, Cerebral vascular accidents, Charles Bonnet disease, Chemotherapy-induced emesis, Childhood autism, Chronic pain, Chronic insomnia, cocaine addiction, Cognitive disorders, craniofacial pain, temporomandibular joint (TMJ) / temporomandibular disorder (TMD), Cushing´s disease, Delusion, Dementia, Dementia with Lewy Body or Lewy Body dementia, dementia and psychosis associated with Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Depression, Diabetes mellitus (non-insulin dependent), Diabetic peripheral neuropathy, Drug addiction, Double vision, Down´s syndrome, Dyskinesia, Dysthymia, Dystonia, Ejaculatory problem, Emphysema, Epilepsy, Extrapyramidal disorder, Fibromyalgia, Frailty, Friedrich´s Ataxia, Frontotemperal Dementia, Gambling associated with ICD, Galactorrhea, General anxiety disorder, Glaucoma, Hair loss or thinning, Hallucination, Headache, Hemorrhoids, Huntington's disease, Hyperprolactinemia, Hypertension, Hypersexuality associated with ICD, Hypotension, Hypoglutamateriga disorders, Impulse control disorder, Idiopathic thrombocytopenic purpura, Impotence, Incontinence, Increased intraocular pressure, Infertility, Inflammatory pain, Insomnia, Ischemia, Ischemic stroke, Lewy body disease (LBD), Learning disorders, Libido (decreased), Loss of libido, Low male fertility, Low sperm mobility, Lupus, Machado-Joseph disease, Major depression, Mania, Menopausal symptoms, Metabolic syndrome, methamphetamine addiction, Migraine, mild cognitive impairment (MCI), Motor tics, Multi-infarct dementia, Multiple sclerosis, Multiplex development disorder, Myocardial infarction, Myoclonus, Neuropathic pain, Neurodegenerative disorder, Neuropsychiatric disease, Nicotine addiction, Non motor symptoms of Parkinson's disease selected from dementia, depression, apathy, hallucinations, dribbling saliva (sialorrhea), constipation, pain, genitourinary problems and sleep disorders, Obsessive compulsive disorder, On/off phenomena, Opioid addiction, Osteoporosis, Pancreatis, Panic attacks, Parkinson's disease, Parkinson's disease dementia, Parkinson's disease psychosis, Periodic limb movement during sleep (PLMS), Peripheral vascular disease, Pituitary tumor, Postherpetic neuralgia, Progressive Supranucelar Palsy, Prion disease including Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Prolactinoma, Pseudobulbar affect (PBA), Psychomotor slowing, Psychosis, Psychoses secondary to neurodegenerative disorders, Psychosomatic disorders, Psychotic depression, post-traumatic stress disorder (PTSD), Raynaud´s disease, Reflex sympathetic dystrophy, Restless legs

syndrome, Retinal disease, Schizoaffective disorders, Schizophrenia, negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia, Sepsis, Serotonin syndrome, Sexual dysfunction, Sexual dysfunction associated with antidepressant use, Sleep apnea, Sleep disorders, Sleep maintenance insomnia, social anxiety disorder, Spinal injury, Spinocerebellar Atrophy, Suicidal tendency, Thrombosis, Thrombotic stroke, Thrombotic thrombocytopenic purpura, Tinnitus, Tiredness, Tourette´s syndrome, Transient insomnia, Traumatic brain injury, Treatment-resistant depression, Treatment-resistant schizophrenia, Tremor, Vaginal dryness, Vasospasm Wakefulness, vascular dementia, Hallucinations associated with Parkinson's disease, Delusions associated with Parkinson's disease; cancer, brain cancer, glioma, Pancreatic cancer, Hypoactive sexual desire disorder, adult type 2 diabetes mellitus with Parkinson's disease or dementia and Liver fibrosis.

57. The compound, or pharmaceutically acceptable salt, hydrate, solvate, polymorph, stereoisomer, and deuterated analogue thereof according to any one of claims 1-55, or a composition comprising an effective amount of a compound, pharmaceutically acceptable salt, polymorph or stereoisomer of a compound according to any one of claims 1-55,
for use in treating a disease selected from the group consisting of Abnormal hormonal activity, Alzheimer's disease, Alzheimer's disease dementia, Alzheimer's disease psychosis, Addiction (alcohol, cocaine, methamphetamine, nicotine and opioid), Addison's disease, ADHD, Alzheimer's disease psychosis, Affective disorders, Aggressiveness, Agitation, Akathisia, Alcohol addiction, Alcohol withdrawal, Amenorrhea, Amyotrophic lateral sclerosis, Anhedonia, Anorexia, Anti-NMDAR encephalitis, Anxiety, Appetite disorders, Asthma, Autism, Behavioral disorders, Behavioral disturbances associated with dementia, Binge eating disorder associated with impulse control disorder (ICD), Bipolar disorder, Blindness, Borderline disorder, Borderline personality disorder, Bradykinesia, Bulimia, Buying associated with ICD, Cardiac arrhythmia, Cerebral vascular accidents, Charles Bonnet disease, Chemotherapy-induced emesis, Childhood autism, Chronic pain, Chronic insomnia, cocaine addiction, Cognitive disorders, craniofacial pain, temporomandibular joint (TMJ) / temporomandibular disorder (TMD), Cushing´s disease, Delusion, Dementia, Dementia with Lewy Body or Lewy Body dementia, dementia and psychosis associated with Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Depression, Diabetes mellitus (non-insulin

dependent), Diabetic peripheral neuropathy, Drug addiction, Double vision, Down´s syndrome, Dyskinesia, Dysthymia, Dystonia, Ejaculatory problem, Emphysema, Epilepsy, Extrapyramidal disorder, Fibromyalgia, Frailty, Friedrich´s Ataxia, Frontotemperal Dementia, Gambling associated with ICD, Galactorrhea, General anxiety disorder, Glaucoma, Hair loss or thinning, Hallucination, Headache, Hemorrhoids, Huntington's disease, Hyperprolactinemia, Hypertension, Hypersexuality associated with ICD, Hypotension, Hypoglutamateriga disorders, Impulse control disorder, Idiopathic thrombocytopenic purpura, Impotence, Incontinence, Increased intraocular pressure, Infertility, Inflammatory pain, Insomnia, Ischemia, Ischemic stroke, Lewy body disease (LBD), Learning disorders, Libido (decreased), Loss of libido, Low male fertility, Low sperm mobility, Lupus, Machado-Joseph disease, Major depression, Mania, Menopausal symptoms, Metabolic syndrome, methamphetamine addiction, Migraine, mild cognitive impairment (MCI), Motor tics, Multi-infarct dementia, Multiple sclerosis, Multiplex development disorder, Myocardial infarction, Myoclonus, Neuropathic pain, Neurodegenerative disorder, Neuropsychiatric disease, Nicotine addiction, Non motor symptoms of Parkinson's disease selected from dementia, depression, apathy, hallucinations, dribbling saliva (sialorrhea), constipation, pain, genitourinary problems and sleep disorders, Obsessive compulsive disorder, On/off phenomena, Opioid addiction, Osteoporosis, Pancreatis, Panic attacks, Parkinson's disease, Parkinson's disease dementia, Parkinson's disease psychosis, Periodic limb movement during sleep (PLMS), Peripheral vascular disease, Pituitary tumor, Postherpetic neuralgia, Progressive Supranucelar Palsy, Prion disease including Creutzfeld-Jakob disease (CJD), Gerstmann-Strausser-Schenker disease (GSSD) and fatal familiar insomnia (FFI), Prolactinoma, Pseudobulbar affect (PBA), Psychomotor slowing, Psychosis, Psychoses secondary to neurodegenerative disorders, Psychosomatic disorders, Psychotic depression, post-traumatic stress disorder (PTSD), Raynaud´s disease, Reflex sympathetic dystrophy, Restless legs syndrome, Retinal disease, Schizoaffective disorders, Schizophrenia, negative symptoms of schizophrenia, cognitive impairment associated with schizophrenia, Sepsis, Serotonin syndrome, Sexual dysfunction, Sexual dysfunction associated with antidepressant use, Sleep apnea, Sleep disorders, Sleep maintenance insomnia, social anxiety disorder, Spinal injury, Spinocerebellar Atrophy, Suicidal tendency, Thrombosis, Thrombotic stroke, Thrombotic thrombocytopenic purpura, Tinnitus, Tiredness, Tourette´s syndrome, Transient insomnia, Traumatic brain injury, Treatment-resistant depression, Treatment-resistant schizophrenia, Tremor, Vaginal dryness,

Vasospasm Wakefulness, vascular dementia, Hallucinations associated with Parkinson's disease, Delusions associated with Parkinson's disease; cancer, brain cancer, glioma, Pancreatic cancer, Hypoactive sexual desire disorder, adult type 2 diabetes mellitus with Parkinson's disease or dementia and Liver fibrosis.